Boothbay Fund Management LLC Purchases New Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Boothbay Fund Management LLC acquired a new position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 537,219 shares of the biopharmaceutical company's stock, valued at approximately $548,000. Boothbay Fund Management LLC owned 0.26% of Sangamo Therapeutics at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the stock. EAM Investors LLC acquired a new position in shares of Sangamo Therapeutics in the 4th quarter valued at $256,000. Barclays PLC lifted its position in Sangamo Therapeutics by 6,324,700.0% in the fourth quarter. Barclays PLC now owns 63,248 shares of the biopharmaceutical company's stock valued at $65,000 after acquiring an additional 63,247 shares during the last quarter. ExodusPoint Capital Management LP acquired a new position in shares of Sangamo Therapeutics in the 4th quarter valued at $42,000. Geode Capital Management LLC increased its position in Sangamo Therapeutics by 3.4% during the 4th quarter. Geode Capital Management LLC now owns 2,211,849 shares of the biopharmaceutical company's stock worth $2,257,000 after purchasing an additional 73,540 shares during the period. Finally, JPMorgan Chase & Co. raised its holdings in shares of Sangamo Therapeutics by 679.5% in the fourth quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 21,793 shares during the last quarter. 56.93% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. HC Wainwright reissued a "buy" rating and set a $10.00 target price on shares of Sangamo Therapeutics in a research report on Monday, April 7th. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $2.00 price target on shares of Sangamo Therapeutics in a research note on Tuesday, March 18th. Finally, Truist Financial decreased their price objective on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating for the company in a report on Thursday, January 23rd. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Sangamo Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $5.17.

Sangamo Therapeutics Trading Down 5.3 %

Shares of SGMO stock traded down $0.04 during trading hours on Tuesday, reaching $0.68. The stock had a trading volume of 1,316,202 shares, compared to its average volume of 8,532,954. The stock's fifty day simple moving average is $0.80 and its 200 day simple moving average is $1.38. Sangamo Therapeutics, Inc. has a 12 month low of $0.30 and a 12 month high of $3.18. The firm has a market capitalization of $156.31 million, a PE ratio of -0.91 and a beta of 1.46.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last released its earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.02). The company had revenue of $7.55 million during the quarter, compared to the consensus estimate of $11.70 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. As a group, equities research analysts anticipate that Sangamo Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.